Abstract P5-15-18: MERIBEL STUDY: Single-agent eribulin as first-line therapy for taxane-resistant HER2[-] metastatic breast cancer (MBC) patients (pts)

Authors :: Antonio Antón
P. Zamora
Casilda Rodríguez
Lourdes Calvo
Maria Martinez-Garcia
Antonio Llombart
JJ Illarramendi
Noemia Afonso
V Ortega
Yolanda Fernández
Mirta García
Elena Aguirre
Esperanza J. Carcache de Blanco
I Garau
José Francisco Pérez
J. Cortés
Source :: Cancer Research. 77:P5-15
Publication Year :: 2017
Publisher :: American Association for Cancer Research (AACR), 2017.
Abstract: This abstract was withdrawn by the authors.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Taxane
business.industry
medicine.disease
Metastatic breast cancer
chemistry.chemical_compound
First line therapy
chemistry
Internal medicine
medicine
Single agent
business
Eribulin

Full Text Access

Tools